Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases

Frequency is pioneering a new category in regenerative medicine, developing small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy, functional tissues.

Sensorineural Hearing Loss (SNHL)

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FX-322-208 Phase 2b Study

Stage: Phase 2

Double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of FX-322 individuals with noise induced and sudden SNHL, aged 18 – 65.

FX-345-101 Phase 1b Study

Stage: Phase 1

Single-blind, placebo-controlled, multicenter study to evaluate the safety of FX-345 in individuals with adult-onset acquired SNHL, aged 18-67

Study enrolling 36 subjects, first subject dosed December 2022

Multiple Sclerosis

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Remyelination program

Stage: Preclinical

Clinical Trials Information

For more information on the phase 2b clinical trial for FX-322, please visit clinicaltrials.gov.

Expanded Access Policy

Learn about our expanded access policy.

Our Program for Sensorineural Hearing Loss

Advancing FX-322 into a Phase 2b clinical study for the most common form of hearing loss

Learn More

Our Program for Multiple Sclerosis

Developing medicines that activate the cells needed to restore myelin, potentially reversing damage done by multiple sclerosis

Learn More